Details

Autor(en) / Beteiligte

• Iida, Shinsuke
• Ishida, Tadao
• Horimoto, Katsuhisa
• Kazama, Hirotaka
• Kim, Hyunchung
• Crawford, Bruce
• Teshima, Takanori

Titel

Medical database analysis of japanese multiple myeloma patients with planned stem cell transplantation (MEDALIST) – a focus on healthcare resource utilization and cost

Ist Teil von

• International journal of hematology, 2021-02, Vol.113 (2), p.271-278

Ort / Verlag

Singapore: Springer Singapore

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• This study explored the burden associated with stem cell mobilization, with or without cyclophosphamide (CPA), in patients who intended to receive autologous stem cell transplantation (ASCT) for multiple myeloma (MM). A Japanese health care claims database (MDV) was used to analyze the health care resource utilization patterns and medical cost between 2013 and 2016 (pre-plerixafor launch). The patients were further categorized into groups who received granulocyte-colony stimulating factor (G-CSF) alone or G-CSF + CPA group and analyzed in both mobilization and ASCT phases of treatment. Overall, there were more MM patients who were treated with G-CSF + CPA combination therapy than G-CSF alone. Length-of-stay was 1.6 times longer in the combination group during the mobilization phase. A reverse trend was observed during the ASCT phase. Direct cost was approximately 1.2 million yen during the mobilization phase and 2.3 million yen during the ASCT phase, with hospitalization basic fee accounting for the highest proportion in both groups and phases. A substantial amount of healthcare resource and cost was consumed in both phases. This study may serve as a basic reference for further health technology assessment of new medicines such as plerixafor. Further investigation of differences between treatment groups is warranted.